Key clinical point: Tofacitinib showed higher efficacy and comparable safety to vedolizumab in patients with ulcerative colitis (UC) with prior treatment failure with anti-tumor necrosis factor (anti-TNF) therapy.
Major finding: Patients treated with tofacitinib vs. vedolizumab were more likely to achieve corticosteroid-free remission at weeks 12 (odds ratio [OR] 6.33; P < .01), 24 (OR 3.02; P < .01), and 52 (OR 1.86; P = .01). The overall risk for adverse events (AE) was higher in patients treated with vedolizumab (OR 1.83; P = .02), whereas the risk for serious AE was similar in both the groups.
Study details: This was a prospective cohort study of 148 patients with UC from the Initiative on Crohn and Colitis (ICC) registry who were treated with vedolizumab (n = 83) or tofacitinib (n = 65) after the failure of treatment with at least one anti-TNF agent.
Disclosures: The ICC fellowship was sponsored by AbbVie, Pfizer, and others. Some authors reported receiving grants, consulting fees, speakers’ fees, presentation fees from, or serving on advisory boards for various sources, including the sponsors of the ICC Fellowship.
Source: Straatmijer T et al. Superior effectiveness of tofacitinib compared to vedolizumab in anti-TNF experienced ulcerative colitis patients: A nationwide Dutch Registry study. Clin Gastroenterol Hepatol. 2022 (May 26). Doi: 10.1016/j.cgh.2022.04.038